A negative correlation between tumor differentiation and MyD88 expression level was observed in embryonic carcinoma (EOC), indicating that MyD88-positive cancer cells were more aggressive with higher adverse biological characteristics, such as resistance to standard platinum and taxane chemotherapy. This evidence concerns the gene MYD88 and embryonal carcinoma.